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Abstract
Clonal cytogenetic evolution (CE) (i.e., acquisition of new chromosomal aberrations over time) is relevant for the
progression of myelodysplastic syndromes (MDS). We performed detailed analysis of CE in 729 patients with MDS and
related disorders. Patients with CE showed shorter survival (median OS 18.0 versus 53.9 months; P < 0.01), higher
leukemic transformation rate (48.0% versus 21.4%; P < 0.01) and shorter intervals to leukemic transformation (P < 0.01).
Two main CE patterns were detected: early versus late CE (median onset 5.3 versus 21.9 months; P < 0.01) with worse
survival outcomes for early CE. In the case of CE, del (7q)/−7 (P= 0.020) and del (17p) (P= 0.002) were especially
unfavorable. Extending the evolution patterns from Tricot et al. (1985) forming ﬁve subgroups, prognosis was best
(median OS not reached) in patients with “transient clones/changing clone size”, whereas those with “CE at diagnosis”
showed very poor outcomes (P < 0.01 for comparison of all). Detailed sequential cytogenetic analysis during follow-up
improves prognostication in MDS patients and acknowledges the dynamic biology of the disease. Evidence, time-
point, and patterns of cytogenetic clonal evolution should be included into future prognostic scoring systems for MDS.
Introduction
In around 50% of patients with myelodysplastic syn-
dromes (MDS), clonal cytogenetic abnormalities are
detectable by conventional chromosome banding (CCB)
from bone marrow metaphases1–3 The karyotype is highly
signiﬁcant for prognostication2–6 and therapy allocation
in patients with MDS and plays a fundamental role for the
International Prognostic Scoring System (IPSS)4, its
revised form, the IPSS-R6,7 and the WHO adapted Prog-
nostic Scoring System8,9. Molecular mutation screening as
well has achieved increasing importance in patients with
MDS10,11. Therapeutic options in patients with MDS are
highly variable including supportive measures, targeted
approaches such as lenalidomide in MDS with isolated 5q
deletion12, and disease-modifying approaches such as
azacitidine or decitabine13,14. Selected patients with high-
risk MDS are candidates for allogeneic hematopoietic
stem cell transplantation; so far the only curative
approach.
Cytogenetic features are heterogeneous in MDS and are
outlined by a preponderance of unbalanced abnormalities.
Losses of chromosomal material (e.g., deletion of 5q or
20q, −7, −Y) are more frequent than gains (e.g., +8 or
21)2,3,15,16. Complex karyotypes (deﬁned by at least three
independent clonal cytogenetic changes)17 amount to 15%
of all MDS and to 30% of all cytogenetically aberrant
cases2–4.
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Myelodysplastic syndromes are supposed to result from
multistep pathogenesis, characterized by increasing
malignant potential and clonal evolution18–20. This
hypothesis suggests a genetic defect on the stem cell level
including activation of oncogenes, inactivation of tumor
suppressor genes, and alteration of cell cycle regulation21.
The course of MDS is characterized by chromosome
instability and fragility. The sequential acquisition of
novel cytogenetic aberrations and the accumulation of
these changes result in detectable clonal evolution. Other
than that, chromothripsis22 occurring in only one cata-
strophic event leading to chaotic and substantial rear-
rangements of the chromosome complement can lead to
end stage comparable to CE. Clonal evolution may be
diagnosed by sequential CCB or by the parallel occurrence
of metaphases at different evolution steps in a single
cytogenetic analysis. Cytogenetic clonal evolution has
been documented in 11.9–39.0% of all MDS cases3,15,23–
26. Only few studies including 30 to >150 patients23,25–27
and one large study (n= 988 patients)28 investigated
progression patterns in patients with MDS. There was no
doubt that clonal cytogenetic evolution was associated
with a worse prognosis and a more rapid and more fre-
quent transformation to s-AML. Tricot et al29. were able
to discriminate four clonal cytogenetic evolution patterns:
category A referred to MDS patients with a stable clone
and low proliferation activity. Patients from category B
showed instable clones but low proliferative capacities.
Category C referred to patients with stable clones but
more pronounced proliferative capacities. Patients from
category D showed unstable clones but pronounced
proliferative capacities29.
We here aimed to perform a most detailed investigation
of clonal cytogenetic evolution in a large cohort of 729
patients mostly with MDS and related myeloid disorders
such as CMML and s-AML. Within our study we aimed
to characterize clonal evolution patterns in detail and to
investigate the prognostic impact of the phenomenon of
cytogenetic clonal evolution focusing as well on distinct
evolution patterns and the complexity of the evolutionary
process.
Material and methods
Patients
The analysis was based on a total of 729 patients with
conﬁrmed MDS (n= 478), chronic myelomonocytic leu-
kemia (CMML) (n= 63), or s-AML (n= 127). The
majority (n= 701 patients; 96.1%) were adults > 16 years,
28 (3.8%) were pediatric patients. There were 429 males
and 300 females (male/female ratio 1.4) with a median age
of 65.6 years (range, 1.0–92.2 years). Inclusion in the
study was based on the availability of cytogenetic follow-
up analyses or detection of cytogenetic clonal evolution
(CE) already at diagnosis. The majority of patients (n=
663; 90.9%) suffered from de novo disease, 66 patients
(9.1%) had therapy-related myeloid disorders (subtypes
are shown in Table 1). A total of 472 (64.7%) patients
received disease-modifying therapies such as azacitidine
or decitabine. Median overall survival of the whole cohort
was 37.5 months (corresponding to 3.1 years). Patients
had mostly been diagnosed and treated at the University
Hospital of Göttingen, Germany; a minority of the sam-
ples had been sent from regional hematologic centers.
Patients were investigated at the Medical University of
Lübeck, Germany (CF and DH) from 1982 to 1993 and at
the University of Göttingen, Germany (DH, KS, and JS),
from 1993 to 2009.
Methods
CCB was performed on bone marrow cultures accord-
ing to standard methods by G-bands using a modiﬁed
GAG-banding technique3,30. From 1995 on, metaphases
were analyzed with the support of the Ikaros software
(Metasystems, Altlußheim, Germany). Karyotypes were
documented according to ISCN17,31. Selected cases were
additionally clariﬁed by 24-color metaphase FISH. In
total, 1208 cytogenetic evaluations were performed in the
729 patients. Follow-up analyses were available in 225
patients with 2–10 consecutive analyses per patient. CE
was diagnosed when metaphases showing additional
clones resulting from CE were detected in parallel to
clones without the corresponding aberrations within a
single CCB analysis. Alternatively, CE was diagnosed by
sequential CCB in case of novel clonal aberrations in
addition to the previous aberrations. Complex karyotypes
were deﬁned by the simultaneous occurrence of three or
more clonal cytogenetic abnormalities.
Table 1 Demographic characteristics and
cytomorphologic subtypes
Demographic parameters Number (%)
Total cohort 729 (100.0)
Males: females (ratio) 429: 300 (1.4)
Median age (range), years 65.6 (1.0–92.2)
Cytomorphologic subtypes
Refractory anemia (RA) 212 (29.1)
Refractory anemia with ringed sideroblasts (RARS) 75 (10.3)
Refractory anemia with excess blasts (RAEB) 125 (17.1)
MDS, unclassiﬁable 61 (8.3)
RAEB in transformation (RAEB-T) 66 (9.1)
s-AML 127 (17.4)
CMML 63 (8.6)
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Statistical analysis
We used SPSS version 20 (IBM, USA). Overall survival
(OS) was calculated according to Kaplan and
Meier, comparisons of survival outcomes were performed
by log rank test. Patients who were alive at the end of
follow-up and patients lost to follow-up were censored.
Frequencies were compared by Pearson's chi
square, independent variables by Mann–Whitney-U.
Fig. 1 a-i: Prognostic impact of clonal evolution, time point of evolution and complexity of the karyotype in combination with evolution regarding
overall survival and leukemia-free survival
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Wilcoxon's test was used for paired samples. Parameters
impacting signiﬁcantly on the probability of survival
by univariate analysis were included into multivariate
analysis which was performed with the support of
proportional hazard regression models. The following
parameters were included in the multivariate analysis: sex,
age (as continuous parameter), disease-modifying therapy
(yes vs. no), hemoglobin ≥ 100 vs. < 100 g/L, neutrophils ≥
1.8 vs. < 1.8 × 109/L, platelets ≥ 100 vs. < 100 × 109/L,
bone marrow blasts (<5% vs. 5–10% vs. 11–20% vs.
21–31% vs. >30%), number of cytogenetic aberrations per
case (0 vs. 1 vs. 2 vs. 3 vs. >3), cytogenetic risk score
according to the IPSS4 (favorable vs. intermediate vs.
adverse), cytogenetic risk score according to the IPSS-R6,7
(very good vs. good vs. intermediate vs. unfavorable vs.
very unfavorable), presence of CE (yes vs. no), CE patterns
expanding the criteria of Tricot29 as described below (A
vs. B vs. C vs. D vs. E). P-levels < 0.05 were considered to
be signiﬁcant.
Results
Frequency of clonal evolution in the total cohort and
within distinct subgroups
CE was detected in 94 patients: in 76 patients at diag-
nosis, in 18 patients during follow-up. Thus, the fre-
quency of CE was 12.9% (n= 94/729) within the
total cohort. When only cytogenetically aberrant cases
were considered, CE occurred by a frequency of 25.8% (n
= 92/356). The frequency of CE was higher in females
than in males (n= 48/300; 16.0% vs. n= 46/429; 10.7%; P
= 0.037). When the different hematologic entities
were compared, the frequency of CE was n= 66/539 in
MDS (12.2%), n= 9/63 in CMML (14.3%), and n= 19/127
(15.0%) in s-AML. The frequency of CE did not
differ signiﬁcantly between the hematologic entities: MDS
versus CMML: P= 0.643 (chi square); n.s.; CMML
versus s-AML: P= 0.902; n.s.; MDS versus s-AML:
P= 0.409; n.s.
For subsequent analysis, patients were assigned to three
groups according to their age at ﬁrst diagnosis of the MDS
(AG1: < 16 years; n= 28; 3.9%; AG2: 16–60 years; n=
225; 31.4%; AG3: > 60 years: n= 464; 64.7%). Twelve
patients could not be assigned to a distinct age group
(1.7%) as the exact time point of the ﬁrst diagnosis was
not available. CE was more frequent in the higher age
groups AG3 and AG2 as compared to AG1 (n= 64/464;
13.8% vs. n= 27/225; 12.0% vs. 2/28; 7.1%; n.s.). The
frequency of CE did not differ signiﬁcantly between
patients with de novo and therapy-related disease (n= 84/
663; 12.7% vs. n= 10/66; 15.2%). When patients were
compared for peripheral blood parameters at diagnosis
(Supplementary Table 1), there was a non-signiﬁcant
trend to lower neutrophil and thrombocyte counts in
patients with CE.
Prognostic impact of clonal evolution
Survival data were available from 68 patients with CE
(events 34) and from 387 patients without CE (events
118). OS was shorter in patients with CE than in those
without (median 18.0 vs. 53.9 months; P < 0.01; Fig 1a).
Survival data were available from 50 patients with CE at
diagnosis (events 27) and from 18 patients with CE
detected during follow-up (events 7). Patients with CE at
diagnosis showed a shorter OS than those without
(median OS 10.9 vs. 32.6 months; P < 0.01; Fig 1b).
Patients with CE at diagnosis showed a higher number
of cytogenetic aberrations per case as compared to
patients with CE during follow-up of the disease (mean
number 4.9; 95%CI: 3.9–5.9; vs. 1.4; 95%CI 0.6–2.1; P <
0.01).
Prognostic impact of the time point of clonal evolution
CE was detected in 18 patients during follow-up by
sequential cytogenetic analyses. Survival data were avail-
able from all these 18 patients: 11 patients were censored
(61.1%); 7 patients had died (38.9%). For separating these
18 patients into two groups according to the time point of
occurrence of CE the median interval from diagnosis was
chosen as threshold. The median interval was 363 days. In
order of practicability, we thus chose a threshold of
365 days for the respective separation: Patients with CE
within the ﬁrst 365 days from diagnosis were classiﬁed as
“early CE” (n= 9), those with CE occurring later than
365 days from diagnosis as “late CE” (n= 9). Within the
subgroup of patients with “early CE” (less than 1 year
from diagnosis), the median time point of detection of CE
was 5.3 months (range, 2.8–10.1 months). The subgroup
with “late CE” (at more than 1 year from diagnosis) was
developing CE after a median of 21.9 months from diag-
nosis within a range from 13.8 to 46.3 months. Thus,
different kinetics of CE became obvious. Patients with
early CE showed shorter OS than those with late CE
(median 13.2 vs. 32.6 months; P= n.s.; Fig 1c). Although
signiﬁcance was not reached (probably due to the limited
case number) this difference in the survival outcomes of
both subgroups as discriminated by the time point of
occurrence of CE suggests a higher level of cytogenetic
instability in the patients with early CE.
Cytogenetic aberrations
Patients with CE more frequently had aberrant kar-
yotypes at diagnosis than those without CE (n= 92/94;
97.9% vs. n= 262/633; 41.4%; P < 0.01).
We performed comparison of survival outcomes
depending on the presence of aberrant karyotypes at
diagnosis and depending on the occurrence of CE. For
this comparison, only three subgroups could be compared
as only two patients initially showed a normal karyotype
and developed CE during follow-up. Patients with a
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normal karyotype at diagnosis without CE showed the
best median OS of 63.8 months. Patients with aberrant
karyotypes at diagnosis without CE showed a median OS
of 32.7 months, those with aberrant karyotypes at diag-
nosis and presence of CE at the time of diagnosis had a
median OS of 18.0 months only and thus were repre-
senting the most unfavorable subgroup (P < 0.01 for
comparison of all subgroups and for all single compar-
isons; Fig 1d).
Cytogenetic complexity
Cytogenetic complexity was categorized according to
the number of clonal cytogenetic aberrations at diagnosis
following the suggestion of Heim and Mitelman32: group
1—no cytogenetic aberration; group 2—one clonal aber-
ration; group 3—two clonal aberrations, group 4—three
clonal aberrations, group 5—more than three clonal
aberrations. Normal karyotypes at the time point of
cytogenetic analysis were rare in patients with CE as
compared to the frequency in patients without CE (n= 2/
94; 2.1% vs. 371/633; 58.6%; P < 0.01). Presence of one
clonal aberration was more frequent in the patients
without CE, whereas presence of 2, 3, and >4 clonal
aberrations at diagnosis was more frequent in patients
with CE (P for comparison of all, P < 0.01; Table 2).
Complex karyotypes (≥3 clonal abnormalities) were found
more frequently at diagnosis in patients with CE than in
patients without: 50 of 92 patients (54.3%) with CE
already at diagnosis or during follow-up vs. 57/264
(21.6%) patients without CE (P < 0.01). Thus, the phe-
nomenon of CE was associated with higher cytogenetic
complexity.
Focusing on patients with CE, median OS of patients
with complex karyotypes at diagnosis was 3.8 months as
compared to 32.6 months for patients with non-complex
karyotypes at diagnosis (P < 0.01). In the subgroup of
patients with complex karyotypes, patients with CE
showed a median OS of 3.8 months as compared to
8.9 months in those without (P < 0.01; Fig 1e).
Size of aberrant clones
The ﬁnding of aberrant metaphases only (i.e., all
metaphases analyzed aberrant) at diagnosis was more
frequent in cases with CE than in those without (38/94;
40.4% vs. 77/623; 12.4); mosaic karyotypes (meaning the
parallel occurrence of aberrant and normal metaphases)
were found in 54/94 (57.4%) of cases with CE as compared
to 176/623 (28.3%) in patients without (P < 0.01). Patients
with CE showed a htranigher mean proportion of 84.8% of
aberrant metaphases at diagnosis as compared to 72.9% in
patients without CE (P < 0.01). In the subgroup of patients
with aberrant metaphases only, patients with CE showed
shorter survival than those without (median OS 6.6 vs.
19.5 months; P= 0.022; Fig 1f). Considering only mosaic
karyotypes, survival of patients with CE was signiﬁcantly
shorter as compared to patients without (median OS 18.0
vs 37.5 months; P= 0.009).
Leukemic transformation
Transformation to s-AML was more frequent in
patients with CE as compared to patients without CE (24/
50; 48.0% vs. 67/313; 21.4%; P < 0.01). Patients without CE
showed a plateau of the LFS, whereas all patients with CE
developed s-AML. The median LFS was 17.5 months in
patients with CE, whereas it was not reached in the sub-
group without CE (Fig 1g). The LFS in the subgroup with
early CE (<365 days from diagnosis) was 6.8 months only
in contrast to 21.0 months in patients with late CE
(occurring more than 365 days from diagnosis; P= 0.241;
Fig 1h). Considering only patients with aberrant meta-
phases only, those with CE showed a median LFS of
6.6 months as compared to 19.5 months in those without
(P= <0.01). When only patients with mosaic karyotypes
were considered, median LFS was 18.0 months in those
with CE whereas median LFS was 37.5 months in those
without (P < 0.01; Fig 1I).
Characterization of involved chromosomes
Most frequently, CE was resulting from aberrations of
chromosomes 5 (n= 51), 7 (n= 35), and 8 (n= 27). This
is shown in more detail in Supplementary Figure 1. Sub-
sequently, distinct chromosomes/chromosomal regions
were considered, in particular 5q deletion, −7/del(7q),
+8, 17p abnormality, 20q abnormality, and −Y.
Patients with CE showed a higher frequency of del(5q)
at diagnosis as compared to those without (43/92; 46.7%
vs. 66/198; 25.0%; P < 0.01). Within the subgroup of
patients with del(5q) at diagnosis, survival data were
available from 25 patients with CE (events 12) and from
33 patients without CE (events 10). Patients with del(5q)
and CE showed a median OS of 18.0 months whereas
median OS was not reached for those with del(5q) with-
out CE (P= 0.031, Fig 2). Within the subgroup of patients
with CE, the median OS did not differ signiﬁcantly
Table 2 Cytogenetic complexity at diagnosis in patients
with and without CE
No. of aberrations per
case
No. (%) P-value
(Chi²)
Pts without CE Pts with CE
0 371 (58.6%) 2 (2.1%) <0.01
1 177 (28.0%) 13 (13.8%)
2 25 (3.9%) 29 (30.9%)
3 16 (2.5%) 9 (9.6%)
>3 44 (7.0%) 41 (43.6%)
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between those with del(5q) and those without del(5q)
(13.3 vs. 18.2 months; n.s.).
Chromosome 7 aberrations—i.e., −7/del(7q)—were
detected in 88 out of all 356 patients with aberrant kar-
yotypes at diagnosis (24.7%). At diagnosis, they did not
differ signiﬁcantly between patients with CE and those
without (n= 27/92 patients; 29.3% vs. 61/264 patients;
23.1%). Survival data were available from 72 patients with
CE (of those, 20 patients with chromosome 7 aberrations).
Within patients with CE, the median OS of patients with
−7/del(7q) was worse as compared to patients without any
chromosome 7 aberration (8.2 vs. 18.2 months; P= 0.020).
Trisomy 8 was detected in 65/356 cases (18.2%) with
aberrant karyotypes with a similar frequency in both
subgroups (i.e., patients with CE and patients without; n=
19; 20.7% vs. n= 46; 17.4%; n.s.). Survival data were
available in 13 cases with CE and +8 (censored in 9 cases)
and in 59 patients without +8 (censored in 31 cases).
Considering only patients with CE, median OS did not
differ signiﬁcantly between those with +8 and those
without +8 (median OS not reached vs. 17.9 months; n.s.).
A total of 8 patients (2.2%) were affected by 17p dele-
tions. 17p deletions were more frequent in patients with
evidence of CE than in cases without (n= 5; 5.4% vs. n=
3; 1.1%; P= 0.030). When only patients with CE were
considered, patients with del(17p) showed a shorter
median OS of 1.8 months as compared to patients without
del(17p) (1.8 vs. 17.9 months; P= 0.002).
20q deletion was detected in patients with and in
patients without CE by a similar frequency (n= 9; 9.8% vs.
n= 15; 5.7%; n.s.). Within the subgroup of patients with
CE, the median OS of patients with del(20q) and of those
without del(20q) did not differ signiﬁcantly (17.9 months
vs. 16.9 months; n.s.).
Loss of the Y chromosome was identiﬁed in male
patients with CE and those without by a similar frequency
(n= 4; 4.3% vs. n= 14; 5.3%; n.s.). Survival data were
available from 72 patients, only 3 of which showed −Y,
which was not sufﬁcient for statistical calculation.
Cytogenetic evolutionary patterns
Extending the criteria of Tricot et al29. to a cytogenetic
basis ﬁve follow-up patterns were deﬁned for this study:
A. “Genetic progression”: cases with an initially normal
karyotype gaining additional aberrations during follow-
up, cases showing an initially abnormal karyotype gaining
further aberrations during follow-up, cases with an
increase of clone size by >20% and cases initially showing
a non-complex karyotype but later transforming into a
complex karyotype. Thus, this category refers to patients
with the phenomenon of CE during follow-up but also to
patients who show genetic progression but no sign of CE
as deﬁned above. B. “Genetic stability”: patients with an
unchanged normal or an unchanged aberrant karyotype
(patients without any sign of CE). C. “Genetic regression”:
patients with an aberrant karyotype at the initial analysis
achieving a reduction of the aberrant clone of more than
20% or transforming to a normal karyotype during follow-
up (possibly related to disease-modifying therapy). D. “CE
at diagnosis”: patients with different but depending clones
showing additional clonal chromosomal aberrations in
parallel to the stem clone. E. “Transient clones/changing
clone size”: patients with transient clones that appear only
temporary or patients that show an undulant clone during
the course of the disease.
We were able to investigate 280 patients for these
cytogenetic evolution patterns: A total of 76 patients
showed CE already at diagnosis of the MDS; for 21 of
those cytogenetic follow-up investigations were available,
whereas 55 patients were investigated only once at diag-
nosis. In addition, cytogenetic follow-up investigations
were available in another 204 patients from the original
cohort. The largest subgroup was identiﬁed for pattern B/
“genetic stability” in 126 patients (45.0%). This was fol-
lowed by pattern A/“genetic progression” in 73 patients
(26.1%); pattern D/“CE already at diagnosis”: n= 55
(19.6%); pattern C/“genetic regression”: n= 18 (6.4%).
The smallest subgroup was represented by pattern E/
“transient clones/changing clone size”: n= 8; 2.9%).
When patients were investigated for the frequencies of
complex karyotypes within these cytogenetic evolution
patterns, these were most frequent in the patients with CE
at diagnosis (pattern D) with 36/54 (66.7%) of patients.
Frequencies of complex karyotypes were detected in the
Fig. 2 Overall survival of patients with 5q-deletion with and without
clonal evolution
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other subgroups as follows: genetic progression (pattern
A): n= 6/54 (11.1%); genetic stability (pattern B): n= 9/
54 (16.7%); “genetic regression” (pattern C): n= 3/54
(5.5%); transient clones/changing clone size (pattern E): n
= 0/54 (0.0%).
Cytogenetic aberrations within clonal evolution
We speciﬁcally focused on the 18 patients in whom CE
was observed during follow-up. The most frequent pri-
mary clonal cytogenetic aberrations at ﬁrst diagnosis
were: del(5q): n= 4; −7/del(7q): n= 3; del(20q): n= 2.
Clonal evolution during follow-up was most frequently
characterized by the occurrence of chromosome 7 aber-
rations—i.e., −7/del(7q)]—or +8 (n= 3 cases each). An
additional –Y was detectable in 2 of these 18 cases. One
case with a normal karyotype at diagnosis proceeded to a
complex karyotype. Another case with a normal karyotype
at diagnosis developed del(5q) and −21. Supplementary
Table 2 shows the karyotypes of patients with CE at
diagnosis and during follow-up.
Occurrence of distinct aberrations within different clonal
evolution patterns
Patients with pattern D/CE at diagnosis showed a high
frequency of del(5q) (n= 32; 58.2%), −7/del(7q) (n= 16;
29.1%), and +8 (n= 11; 20.0%). 17p aberrations were
found in four cases (7.3%). Patients with pattern A/
“genetic progression” showed −7/del(7q) and del(5q) in
12 cases (16.4%) each. Trisomy 8 was detected in 8 cases
(11.0%). Del(20q) (n= 6; 8.2%) was less frequent. Patients
with pattern B/“genetic stability” showed most frequently
+8 (n= 10; 7.9%). Patients with pattern C/“genetic
regression” frequently showed −7/del(7q) (n= 5; 27.8%).
In patients with pattern E/“transient clones/changing
clone size”, del(5q) was found in three cases (37.5%). −7/
del(7q), del(20q) and 17p aberrations were not detectable.
Thus, −7/del(7q) was occurring in all evolution patterns
but “transient clones/changing clone size” (pattern E).
Supplementary Figure 2 illustrates associations between
distinct chromosomal aberrations and the different clonal
evolution patterns.
Prognostic proﬁles according to clonal evolution patterns
Prognosis was best with median OS not being reached
in patients with pattern E/“transient clones/changing”
clone size. Patients with pattern B/“genetic stability”
showed a very favorable median OS of 186.8 months,
patients with pattern A/“genetic progression”:
47.2 months, pattern C/“genetic regression”: 37.5 months.
Those with pattern D/“CE at diagnosis” showed median
OS of 3.6 months only (P < 0.01 for comparison of all
subgroups; Fig 3).
Univariate and multivariate analysis
Supplementary Table 3 shows the results of uni- and
multivariate analysis for prognostically relevant para-
meters. By univariate analysis for parameters impacting
on the OS, patients with CE showed a 2.7-fold increased
HR (P < 0.01). When patients were grouped according to
the peripheral blood thresholds given by the IPSS4,
hemoglobin < 100 g/L (P < 0.01), neutrophils < 1.8 × 109/L
(P= 0.013), and thrombocytes < 100 × 109/L (P < 0.01)
were associated with a higher HR. Increased bone marrow
blasts were also associated with a higher HR (P < 0.01).
Presence of CE was linked with a HR of 2.7 (P < 0.01).
Patients with pattern D/“CE already at diagnosis” had a
HR of 11.3 (P < 0.01) as compared to the reference group
pattern A/“genetic progression”. Presence of 3 and of >3
clonal aberrations was associated with increased HRs of
6.7 and 9.4 (P < 0.01 for both). Also the cytogenetic risk
groups according to the IPSS4 and the IPSS-R6,7 sig-
niﬁcantly impacted on OS. Age and sex showed non-
signiﬁcant trends only. Application of disease-modifying
treatment showed no signiﬁcant impact on OS.
All above parameters but the cytogenetic risk groups
according to IPSS and IPSS-R were included into multi-
variate analysis for parameters impacting on the OS
(Supplementary Table 3). Higher bone marrow blasts
maintained their signiﬁcant adverse impact on OS. Pre-
sence of three clonal cytogenetic aberrations was
Fig. 3 Overall survival of patients categorized into different clonal
evolution patterns
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associated with a HR of 5.7, presence of >3 aberrations
with a HR of 8.3 (P < 0.01 for both). Presence of CE was
associated with an increased HR of 3.6 (P= 0.013).
Patients with “genetic stability” and “CE already at diag-
nosis” had a higher risk of mortality (HR for pattern B: 2.0;
for pattern D: 1.9; P= n.s.). Patients with “genetic
regression” and those with transient clones/changing
clone size showed a reduced risk of mortality (HR for
pattern C: 0.4; for pattern E: 0.6; P= n.s).
Discussion
In this study, we evaluated the prognostic impact of CE
and of distinct clonal evolution patterns at diagnosis and
during follow-up in 729 patients with MDS and related
disorders (CMML and s-AML). So far, only few studies
were focusing on this issue in larger patient cohorts.
Tricot et al. investigated progression patterns including
cytogenetic changes and clinical proﬁles in 46 patients29.
Some more authors were investigating cohorts with
<5024,33,34 or <100 patients23,26. The largest cohorts with
100–200 patients were published by Geddes et al27. and
White et al15. Haferlach et al. presented data of 988
patients at an international conference but did not dif-
ferentiate distinct CE patterns28. At present, molecular
evolution patterns are being evaluated in patients with
MDS by means of high-throughput sequencing 35.
The overall frequency of cytogenetic CE was 12.9% in
our cohort, and we found an association of CE with male
gender. When only cases with aberrant karyotypes were
considered, the frequency of CE was 25.9% which was in
the range of the previous literature (documenting CE in a
range between 10 and 40%) 15, 24 This range may be due
to heterogeneous patient cohorts and varying follow-up
periods in the different studies.
We found CE to be clearly associated with an adverse
prognosis with a median OS of 18.0 months only in
patients with CE in contrast to 53.9 months in those
without (P < 0.01). This was in conﬁrm of previous data
describing more adverse survival outcomes in patients
with CE as compared to those without23,26,27. Beyond that,
we were able to show for the ﬁrst time that the time point
of CE is also relevant. Patients with CE already at diag-
nosis showed an inferior median OS of 10.9 months as
compared to 32.6 months in patients developing CE
during follow-up (P < 0.01). As CE at diagnosis was
detected due to the parallel occurrence of different clones
at initial investigation, these patients may have already
developed advanced disease with several steps of cytoge-
netic evolution before the clinical manifestation which
triggered the investigation for and the diagnosis of the
respective myeloid malignancy. Interestingly, we were
able to discriminate different dynamics of CE during
follow-up. Patients developing CE during the ﬁrst year
from diagnosis showed more adverse survival outcomes
than those developing CE at >12 months. This suggests
that occurrence of CE at an earlier time point may be
associated with higher levels of genetic instability. A sig-
niﬁcant association between CE and rapid leukemic
transformation had been demonstrated also in previous
studies 23,26,27,29,36.
The occurrence of distinct chromosome abnormalities
within CE, i.e., of chromosomes 7 or 17p, was associated
with a signiﬁcantly shorter OS. Thus, the types of chro-
mosomal abnormalities occurring during the process of
CE are also relevant.
The frequency of s-AML transformation was higher
with 48.0% in cases with CE as compared to 21.4% in
those without in our study, and the LFS was signiﬁcantly
shorter (P < 0.01). Bernasconi et al. found a 36-fold
increased risk of leukemic transformation in patients
with CE25. Progression of MDS is considered to be
mediated by stepwise acquisition of novel clonal aberra-
tions18–20. In our study, a higher number of cytogenetic
aberrations at diagnosis showed signiﬁcant association to
the presence of CE. In patients with CE, those with
complex karyotypes showed signiﬁcantly worse survival
outcomes. Furthermore, complex karyotypes showed a
double as high frequency in patients with CE as compared
to those without. Similarly, Haferlach et al. demonstrated
an association of CE with an increase of cytogenetic
complexity28 which also correlates with higher risk IPSS
and IPSS-R scores. Increase of the clonal size had been
shown to be prognostically relevant in MDS
patients15,27,37. In our study, patients with CE with a 100%
clonal size (only aberrant metaphases traceable) had a
signiﬁcantly worse OS as compared to those with CE
affecting only part of the metaphases.
The most frequent primary aberrations in cases devel-
oping CE were del(5q), −7/del(7q), del(20q), and –Y in
our cohort which was corresponding to the well-known
frequent occurrence of the respective abnormalities in
MDS4,6,7. Similarly, Jabbour et al. had described chro-
mosome 7 aberrations in 20% and trisomy 8 in 15% of
patients with CE in a lower risk MDS cohort38. Thus, we
were able to conﬁrm previous studies regarding primary
and secondary aberrations in patients with MDS39–41. The
overall spectrum of chromosomal abnormalities in the
cases with CE in our study was large including, e.g., rare
numerical aberrations such as −22. Finally, −7/del(7q)
was prognostically unfavorable when occurring within CE
(P= 0.020) in analogy to the adverse prognostic impact of
chromosome 7 aberrations 6,7.
Extending and modifying the criteria of Tricot et al29. to
a merely cytogenetic categorization, the best survival was
observed in patients with “transient clones/changing
clone size”, whereas those with “CE already at diagnosis”
had very poor outcomes. One may only speculate that
transient changes have less signiﬁcance as they may
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correlate to only transient periods of cytogenetic
instability. Also, disappearance of pre-existing clones
could be indicative for presence of a more competent
immuno-surveillance. Considering the limited size of
these cytogenetic subgroups further investigation of these
associations by independent study groups is desirable.
In conclusion, we were able to conﬁrm cytogenetic
clonal evolution to represent an independent adverse
prognostic factor for patients with MDS and related
myeloid disorders. Furthermore, our study emphasizes the
value of sequential cytogenetic monitoring during follow-
up of MDS for detecting CE. The detection of CE already
at diagnosis is prognostically more adverse as compared
to its occurrence during the later follow-up. Current risk
stratiﬁcation systems do not focus on disease dynamics in
MDS4,7. According to our results and previous studies,
MDS research should focus on integrating clonal cyto-
genetic evolution and the different clonal evolution pat-
terns into already established risk stratiﬁcation systems in
the near future.
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